Current Clinical Trials

Breast Cancer Clinical Trials:

Alliance A011106 (ALTERNATE)
Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant Treatment (ALTERNATE) in postmenopausal women: A phase III study

Genentech ML28257 (SystHERs Registry) 
An observational cohort study of treatment patterns and outcomes in patients with HER2 positive metastatic breast cancer

Lung Cancer Clinical Trials:

Amgen 20120249
A randomized, multi-center phase 2 Trial of Denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer

Alliance A151216 (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Alliance A081105 (ALCHEMIST)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLS)

Alliance E4512 (ALCHEMIST)
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Prostate Cancer Clinical Trials:

Alliance A031201
Phase III: Enzalutamide versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer

Multiple Myeloma Clinical Trials:

Amgen 20090482
Randomized, double-blind multicenter study of Denosumab compared with zoledronic acid in the treatment of bone disease in subjects with newly diagnosed multiple myeloma

Celgene CC-4047-MM-014
Phase 2, multicenter, single-arm, open label study of Pomalidomide in combination with low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma following Lenolidomide plus Dexamethasone in the second-line setting

Website for all clinical trials:

If you require assistance navigating this website, or want more information about our clinical trials, please contact research manager Corilynn Hughes, R.N., B.S.N., O.C.N., at 410-871-6400.